I'll remember the people who died suffering from lung cancer.
A new drug came out of Korea. First U.S. FDA Approved for Korean Anti-cancer Drugs
유한양행 폐암 신약,
美 FDA 승인…
국산 항암제 최초
Yuhan Corporation’s new drug for lung cancer,
Approved by the US FDA…
The first domestically produced anticancer drug
![](https://blog.kakaocdn.net/dn/brqbQN/btsI9P8ZbL1/iQub6HvkVD8nOxvirjQ5Yk/img.jpg)
Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration Approval
유한양행 폐암치료제 '렉라자'와 '라이브레반트' 병용, 미국 식품의약국(FDA) 최초 승인 획득
https://www.thebionews.net/news/articleView.html?idxno=8021
Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration
[by Yoo, Ha Eun] The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s LECLAZA (US product name: LAZCLUZE) in combination with Johnson &
www.thebionews.net
https://www.thebionews.net/news/articleView.html?idxno=8021
Yuhan Corporation's Lung Cancer Drug 'LECLAZA' in combination with 'RYBREVANT' Receives First U.S. Food and Drug Administration
[by Yoo, Ha Eun] The U.S. Food and Drug Administration (FDA) has approved Yuhan Corporation’s LECLAZA (US product name: LAZCLUZE) in combination with Johnson &
www.thebionews.net
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment fo
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus...
www.prnewswire.com
유한양행, '렉라자' 美 FDA 허가 소식에 12%대 급등[핫스탁]
유한양행이 비소세포폐암 치료제 렉라자의 미국 식품의약국(FDA) 허가 소식에 장 초반 급등세다. 21일 한국거래소에 따르면 오전 9시3분 현재 유한양행은 전일 대비 1만1700원(12.45%) 오른 10만5700원
n.news.naver.com
'관심거리 Interests' 카테고리의 다른 글
전기료 30만원이상 19만 가구 (0) | 2024.09.10 |
---|---|
오래 쓴 나무젓가락 버려야 4인가족 잇따라 간암 사망 (0) | 2024.08.27 |
[날씨] 한반도 향하는 첫 태풍...세력 약해도 "방심은 금물" (0) | 2024.08.20 |
여의도 하늘에 '서울달' 떴다…130m 상공 비행,서울워커 (0) | 2024.08.15 |
뱃속 태아까지 해부 일본노병, 일본 731부대 만행 사죄 (0) | 2024.08.14 |